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Abstract: Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that 
has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid 
metabolism, and blood clotting. Raloxifene signiﬁ  cantly improves serum lipids and serum 
markers of cardiovascular disease risk, but it has no signiﬁ  cant effect on the risk of primary 
coronary events. A meta-analysis of randomized, double-blind, placebo-controlled trials of 
raloxifene for osteoporosis showed the odds of fracture risk were 0.60 (95% conﬁ  dence interval 
[CI] = 0.49–0.74) for raloxifene 60 mg/day compared with placebo. During 8 years of follow-up 
in an osteoporosis trial, the raloxifene group had a 76% reduction in the incidence of invasive 
ER-positive breast cancer compared with the placebo group. In the STAR trial, the incidence of 
invasive breast cancer was 4.30 per 1000 women-years with raloxifene and 4.41 per 1000 with 
tamoxifen; RR = 1.02; 95% CI, 0.82–1.28. The effect of raloxifene on invasive breast cancer was, 
therefore, equivalent to that of tamoxifen with more favorable rates of adverse effects including 
uterine malignancy and clotting events. Millions of postmenopausal women could derive net 
beneﬁ  t from raloxifene through reduced rates of fracture and invasive breast cancer.
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Introduction
Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that has 
antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, 
lipid metabolism, and blood clotting (Vogel 2007). Tamoxifen is the prototypical 
SERM and reduces the risk of both in situ and invasive breast cancers by half when 
compared with placebo (Riggs and Hartmann 2003; Swaby et al 2007). The limitations 
on the use of tamoxifen for breast cancer risk reduction relate to its well-known, but 
rare, side effects. A number of clinical trials established the beneﬁ  t of raloxifene on 
osteoporosis and fracture. Raloxifene signiﬁ  cantly improves serum lipids and serum 
markers of cardiovascular disease risk, but it has no signiﬁ  cant effect on the risk of 
primary coronary events. In the several osteoporosis trials and one heart disease trial, 
raloxifene decreased the risk of estrogen receptor-positive breast cancer by 44% to 90%. 
In the STAR trial, the effect of raloxifene on invasive breast cancer was equivalent 
to that of tamoxifen with more favorable effects on uterine malignancy and clotting 
events. Symptomatic side effects are acceptable. In total, the available data indicate 
that raloxifene represents an acceptable alternative to tamoxifen for the reduction of 
the risk of postmenopausal breast cancer in high-risk women. The potential market 
for a compound shown to reduce the risk of breast cancer in postmenopausal women 
who are at increased risk for breast cancer is more than 10 million women in the 
US alone.Clinical Interventions in Aging 2008:3(4) 602
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Rationale for raloxifene 
and overview of pharmacology
Raloxifene hydrochloride is a SERM that has both 
antiestrogenic and estrogenic effects on breast and 
endometrial tissue and estrogenic effects on bone, lipid 
metabolism, and blood clotting (Bryant et al 1996; Delmas 
et al 1997; Grese et al 1996; Sato et al 1994). It is a 
benzothiophene with characteristics similar to but distinct 
from the triphenlyethylene SERMs such as tamoxifen.
In vitro, raloxifene binds to both the alpha and beta 
subtypes of the estrogen receptor (ERα and ERβ, respectively) 
(Clemett and Spencer 2000). Compared with 17β-estradiol, 
raloxifene has a relative binding afﬁ  nity of 46% at the human 
ERα and 26% at the rat ERβ. In functional transactiva-
tion studies, raloxifene antagonizes 17β-estradiol-induced 
estrogen response element (ERE)-mediated activity via both 
ERα and ERβ. These distinct ER-ligand conformations 
appear to recruit different coactivators and corepressors onto 
the promoter of a target gene by differential protein-protein 
interactions at the receptor surface. Raloxifene acts as a partial 
agonist in bone but does not stimulate endometrial prolif-
eration in postmenopausal women, presumably due to some 
combination of differential expression of transcription factors 
in the two tissues and the effects of this selective estrogen 
receptor modulator on ER conformation (Jordan 2006).
Efﬁ  cacy and comparative studies 
in osteoporosis
During the past decade, a number of clinical trials have been 
conducted to assess the beneﬁ  t of raloxifene on osteoporosis 
and fracture. After the publication of the results of the Breast 
Cancer Prevention Trial (BCPT) (Fisher et al 1998, 2005), 
these osteoporosis trials reported data related to the incidence 
of invasive breast cancer among women taking raloxifene 
compared to those taking placebo. These trials will be 
reviewed here, emphasizing their designs and the reported 
effects of raloxifene on both osteoporosis and the incidence 
of invasive breast cancer.
The MORE Trial
The Multiple Outcomes of Raloxifene Evaluation (MORE) 
trial was a multicenter, randomized, double-blind trial, in 
which women taking raloxifene or placebo were followed 
for a median of 40 months, from 1994 through 1998, at 
180 clinical centers composed of community settings and 
medical practices in 25 countries, mainly in the US and 
Europe (Cummings et al 1999, 2002; Ettinger et al 1999; 
Cauley et al 2001; Lippman et al 2001; Grady et al 2004). 
Participants were a total of 7705 postmenopausal women 
with osteoporosis who were younger than 81 years (mean 
age, 66.5 years). They were randomly assigned to receive 
raloxifene, 120 mg, raloxifene 60 mg/day, or placebo.
The CORE Trial
The Continuing Outcomes Relevant to Evista (CORE) trial 
was conducted to examine the effect of 4 additional years of 
raloxifene therapy on the incidence of invasive breast cancer in 
women in MORE who agreed to continue in CORE (Martino 
2004; Lippman 2006). 3510 women who had been randomly 
assigned to receive raloxifene (either 60 or 120 mg/day) in 
MORE were assigned to receive raloxifene 60 mg/day in 
CORE. Women who had been assigned to receive placebo 
in MORE continued on placebo in CORE (n = 1703).
Effects on osteoporosis
After 36 months of the evaluation in 6828 women in the 
MORE trial, 7.4% had at least one new vertebral fracture, 
including 10.1% of women receiving placebo, 6.6% of 
those receiving 60 mg/day of raloxifene, and 5.4% of those 
receiving 120 mg/day (Ettinger 1999). The risk of verte-
bral fracture was reduced 30%–50% in both study groups 
receiving raloxifene. The frequency of vertebral fracture was 
reduced both in women who did and did not have prevalent 
fracture, but the risk of non-vertebral fractures was not 
signiﬁ  cantly reduced by raloxifene. Compared with placebo, 
raloxifene increased bone mineral density in the femoral 
neck by about 2% and in the spine by 2.6% (p  0.001 for 
all comparisons). Therefore, in postmenopausal women with 
osteoporosis, raloxifene increased bone mineral density in 
the spine and femoral neck and reduced risk of vertebral 
fracture. There was no demonstrated effect on the risk of 
hip fracture, and no further reduction in the incidence of 
vertebral fractures after 4 years of therapy over that seen in 
the ﬁ  rst 3 years (Delmas et al 2002).
A post-hoc analysis of the MORE osteoporosis treatment 
trial assessed the risk-beneﬁ  t proﬁ  le of raloxifene in 7705 
postmenopausal women (Barrett-Connor 2004). A major 
disease outcomes global index resulted in annual rates of 
1.39% and 1.83% in the raloxifene and placebo groups, 
respectively (hazard ratio [HR], 0.75; 95% CI, 0.62–0.92), 
compatible with a favorable risk-beneﬁ  t proﬁ  le for raloxifene 
for treating postmenopausal osteoporosis. In the RUTH trial 
(Barrett-Connor 2006) raloxifene reduced the risk of clinical 
vertebral fractures (HR = 0.65; 95 percent CI, 0.47 to 0.89; 
absolute risk reduction, 1.3 per 1000).Clinical Interventions in Aging 2008:3(4) 603
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A meta-analysis of all randomized, double-blind, 
placebo-controlled trials has been published and was 
performed to determine whether the reduction in the risk 
for vertebral fracture reported with raloxifene was consis-
tent among studies, and to deﬁ  ne more accurately the point 
estimate of the odds ratio (Seeman 2006). Three osteoporosis 
prevention studies (Jolly 2003), two arms of the MORE 
trial (Ettinger 1999), and two additional treatment studies 
(Morii 2003; Lufkin 1998) in which fracture data were avail-
able from prospectively scheduled spinal radiographs were 
included in the analysis. The effects of raloxifene 60 mg/day 
and 120 mg/day pooled with 150 mg/day were analyzed 
using an intention to treat analysis to minimize biases. 
There was no signiﬁ  cant heterogeneity among the studies 
included in the meta-analysis. Odds ratio estimates for the 
reduction of fracture risk were 0.60 (95% conﬁ  dence interval 
[CI] = 0.49–0.74) for raloxifene 60 mg/day and 0.51 (95% 
CI 0.41–0.64) for raloxifene 120 mg/day and 150 mg/day. 
These data indicate that raloxifene consistently reduces the 
risk of vertebral fracture in postmenopausal women.
Despite these data, some experts consider raloxifene to 
be second-line therapy (after bisphosphonates and calcium) 
to be used only in younger postmenopausal women with 
vertebral osteoporosis given its lack of efﬁ  cacy in preventing 
hip fracture (Poole 2006).
The RUTH Trial
Raloxifene therapy has been associated with improvement 
in the levels of serum lipoprotein cholesterol, ﬁ  brinogen, 
and homocysteine. The favorable effect of raloxifene on 
markers of cardiovascular risk, coupled with evidence from 
observational studies that treatment with estrogen was associ-
ated with a reduced risk of coronary heart disease (CHD) in 
postmenopausal women, led to the design of the Raloxifene 
Use for The Heart (RUTH) trial to determine the effect of 
raloxifene on clinical coronary events (Barrett-Connor et al 
2006). In the trial, 10,101 postmenopausal women (mean age 
67.5 years) with CHD or multiple risk factors for CHD were 
randomly assigned either to 60 mg of raloxifene daily or 
placebo and were followed for a median of 5.6 years. The 
two primary outcomes were coronary events (ie, death from 
coronary causes, myocardial infarction, or hospitalization 
for an acute coronary syndrome) and invasive breast cancer. 
There was no increase in cardiovascular disease including 
coronary events (myocardial infarction, unstable angina, or 
coronary ischemia) or cerebrovascular events (stroke or tran-
sient ischemic attack) in the osteoporosis treatment trials that 
compared raloxifene with placebo (Barrett-Connor 2002). 
The breast cancer outcome data from the RUTH trial are 
described below.
Efﬁ  cacy and comparative studies 
in breast cancer risk reduction
The clinical trials that looked at invasive breast cancer as an 
endpoint are summarized in Table 1.
MORE Trial
In the MORE trial (Cummings et al 1999, et al 2002; 
Ettinger et al 1999; Cauley et al 2001; Lippman et al 2001; 
Grady et al 2004), 13 cases of breast cancer were conﬁ  rmed 
among the 5129 women assigned to raloxifene vs 27 
among the 2576 women assigned to placebo (RR = 0.24; 
95% CI = 0.13–0.44; p  0.001). To prevent 1 case of 
breast cancer, 126 women would need to be treated in this 
older population of low to average-risk women. Raloxifene 
decreased the risk of estrogen receptor-positive breast cancer 
by 90% (RR, 0.10; 95% CI, 0.04–0.24), but not estrogen 
receptor-negative invasive breast cancer.
Pre-specified subgroups in the MORE trial were 
deﬁ  ned by age (65 versus 65 years), age at menopause 
(9 vs 49 years), body mass index (25 vs 25 kg/m2), 
family history of breast cancer, serum estradiol level (5–10 
vs 5, 10 vs 5 pmol/L), prior estrogen therapy, and 
bone mass at baseline entry into the MORE trial, and 5-year 
predicted risk of breast cancer that was assessed using the 
modiﬁ  ed Gail model. In the placebo group, older age, higher 
estradiol level, and a family history of breast cancer were 
associated with an increased breast cancer risk (p  0.05). 
Raloxifene therapy was associated with a reduced breast 
cancer risk in both women at lower and those at higher 
breast cancer risk. The therapy by family history interac-
tion was signiﬁ  cant (p = 0.04) indicating a greater beneﬁ  t 
in those women reporting a history of breast cancer in their 
ﬁ  rst-degree relatives.
CORE Trial
During the 4 years of the CORE trial, there were 61 cases 
of breast cancer (30 in the placebo group and 31 in the 
raloxifene group) that were confirmed by adjudication 
(Martino et al 2004; Lippman et al 2006). Of the 61 breast 
cancer cases, 52 cases (28 in the placebo group and 24 in 
the raloxifene group) were classiﬁ  ed as invasive breast 
cancer. Women in the raloxifene group had a 59% reduc-
tion in the incidence of invasive breast cancer compared 
with women in the placebo group (2.1 versus 5.2 cases 
per 1000 woman-years; HR = 0.41, 95% CI = 0.24–0.71). Clinical Interventions in Aging 2008:3(4) 604
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The ER status was determined for 46 of the 52 cases of 
invasive breast cancer; 36 cases (78%) were ER positive. 
Women in the raloxifene group had a 66% reduction in the 
incidence of invasive ER-positive breast cancers compared 
with women in the placebo group (1.3 vs 3.9 cases per 
1000 woman-years; HR = 0.34, 95% CI = 0.18–0.66). By 
contrast, the incidence of invasive ER-negative breast cancer 
in women who received raloxifene was not different from 
that in women who received placebo. The overall incidence 
of breast cancer, regardless of invasiveness, was reduced 
by 50% in the raloxifene group compared with the placebo 
group (2.7 vs 5.5 cases per 1000 woman-years; HR = 0.50, 
95% CI = 0.30–0.82).
For the 7705 MORE participants, the total number of 
reported breast cancers conﬁ  rmed by adjudication from 
randomization in MORE to the end of their participation in 
either MORE or CORE was 121 (56 cancers in the raloxifene 
group and 65 cancers in the placebo group). During these 
8 years, 40 invasive breast cancers were reported in the 
raloxifene group (1.4 cases per 1000 woman-years) and 58 
invasive breast cancers were reported in the placebo group 
(4.2 cases per 1000 woman-years).
The raloxifene group, therefore, had a 66% reduction in 
the incidence of invasive breast cancer compared with the 
placebo group (HR = 0.34, 95% CI = 0.22–0.50). ER status was 
determined for 88 cases, and 75% of these were ER positive. 
During these 8 years, the raloxifene group had a 76% reduc-
tion in the incidence of invasive ER-positive breast cancer 
compared with the placebo group (0.8 vs 3.2 cases per 1000 
woman-years; HR = 0.24; 95% CI = 0.15–0.40). There was 
no difference in the incidence rates of invasive ER-negative 
breast cancer between the raloxifene group and the placebo 
group. There was no statistically signiﬁ  cant difference in the 
incidence of noninvasive breast cancers reported in the two 
treatment groups (16 cases for the raloxifene group vs 7 cases 
for the placebo group; HR = 1.12, 95% CI = 0.46–2.73; 
p = 0.80). During the 8 years of the MORE and CORE trials, 
the overall incidence of breast cancer, regardless of invasive-
ness, was reduced by 58% in the raloxifene group compared 
with the placebo group (HR = 0.42, 95% CI = 0.29–0.60; 
P  0.001).
RUTH Trial
In the RUTH trial (Barrett-Connor et  al 2006), 
raloxifene reduced the risk of invasive breast cancer 
in lower risk, older women by 44 percent (HR = 0.56; 
95% CI = 0.38–0.83). Similar to the ﬁ  ndings in the MORE 
and CORE trials, raloxifene primarily reduced the incidence 
Table 1 Breast cancer risk reduction in studies with raloxifene
Study MORE CORE RUTH STAR
Number of women taking 
raloxifene
5129 3570 5044 9745
Number of women in the 
comparison group
2576 1703 5057 9726
Comparison drug Placebo Placebo Placebo Tamoxifen
Mean age at study entry 66.5 66.2 67.5 58.5
Average follow-up time 40 months 48 months 5.6 years 47 months
No of breast cancers in the 
raloxifene group
13 40 40 168
Event rate in the raloxifene 
group (per 1000 woman-
years)
0.9 1.4 1.5 4.4
No of breast cancers in the 
comparison group
27 58 70 163
Event rate in the comparison 
group (per 1000 woman-
years)
3.6 4.2 2.7 4.3
Risk reduction (hazard 
rate or risk ratio) and 95% 
conﬁ  dence interval
0.24 0.34 0.56 Not 
applicable 
(no placebo 
group) (0.13–0.44) (0.22–0.50) (0.38–0.83)
Reprinted with permission from Vogel VG. 2007. Raloxifene: a second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in 
postmenopausal women. Women’s Health, 3:139–53. Copyright © Future Medicine Ltd.Clinical Interventions in Aging 2008:3(4) 605
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of estrogen-receptor-positive invasive breast cancer: the 
absolute risk reduction per 1000 women treated with raloxi-
fene for one year was 1.2 cases of estrogen-receptor-positive 
invasive breast cancer.
The STAR Trial
To compare the relative effects and safety of raloxifene 
and tamoxifen on the risk of developing invasive breast 
cancer and other disease outcomes, the NSABP conducted 
the Study of Tamoxifen and Raloxifene (STAR) trial, a 
prospective, double-blind, randomized clinical trial that 
began July 1, 1999 in nearly 200 clinical centers throughout 
North America (Land et al 2006; Vogel 2006). Patients were 
19,747 postmenopausal women of mean age 58.5 years 
with increased 5-year breast cancer risk (mean risk, 
4.03 ± 2.17%) as estimated by the Gail model. Participants 
were randomly assigned to receive either tamoxifen at a 
dose of 20 mg/day or raloxifene 60 mg/day over 5 years. 
Outcomes of interest were incidence of invasive breast 
cancer, uterine cancer, noninvasive breast cancer, bone frac-
tures, and thromboembolic events. The trial was designed to 
assess statistical equivalence of the two therapies and was 
powered to report data when 327 cases of invasive breast 
cancer occurred.
After a median of 3.2 years of therapy in the STAR trial 
(Vogel 2006), there were 163 cases of invasive breast cancer 
in women assigned to tamoxifen and 168 in those assigned 
to raloxifene (incidence, 4.30 per 1000 vs 4.41 per 1000; 
RR = 1.02; 95% CI, 0.82–1.28). The cumulative incidence 
through 72 months for the 2 treatment groups was 25.1 
and 24.8 per 1000 for the tamoxifen and raloxifene groups, 
respectively (p = 0.83). When the treatment groups were 
compared by baseline categories of age, history of LCIS, 
history of atypical hyperplasia, Gail model 5-year predicted 
risk of breast cancer (Gail et al 1989; Gail and Costantino 
2001), and the number of relatives with a history of breast 
cancer, the pattern of no differential effect by treatment 
assignment remained consistent. There were no differences 
between the treatment groups in regard to distributions by 
tumor size, nodal status, or estrogen receptor level.
There were fewer cases of noninvasive breast cancer in 
the tamoxifen group (57 cases) than in the raloxifene group 
(80 cases) (incidence, 1.51 vs 2.11 per 1000; RR, 1.40; 
95% CI, 0.98–2.00). Cumulative incidence through 6 years 
was 8.1 per 1000 in the tamoxifen group and 11.6 in the 
raloxifene group. About 36% of the cases were lobular 
carcinoma in situ (LCIS) and 54% were ductal carcinoma in 
situ (DCIS), with the balance being mixed types. The pattern 
of fewer cases among the tamoxifen group was evident for 
both LCIS and DCIS.
Safety and tolerability
Effects on cardiovascular events
The effect of raloxifene on the incidence of cardiovascular 
adverse events in postmenopausal women has been reported 
in the MORE and CORE trials (Dayspring et al 2006; 
Ensrud et al 2006). Of the 7705 participants originally 
enrolled in MORE, 4011 were enrolled in CORE. The 
8-year incidence of serious cardiovascular adverse events 
did not differ signiﬁ  cantly between the raloxifene (5.5%) and 
placebo (4.7%) groups (HR = 1.16, 95% CI = 0.86–1.56). 
Similar results were obtained when coronary (HR = 1.22, 
95% CI 0.82–1.83) or cerebrovascular (HR = 1.19, 95% CI 
0.78–1.84) events were analyzed separately, and when car-
diovascular events were analyzed in the 459 MORE-CORE 
participants who were at increased risk of cardiovascular 
events using previously established criteria (HR 1.03, 95% 
CI 0.58–1.82). Thus, there was no evidence of either a ben-
eﬁ  cial or harmful effect of raloxifene on the incidence of 
cardiovascular events overall, or coronary or cerebrovascular 
events, in postmenopausal osteoporotic women who were 
at relatively low risk of cardiovascular events.
Consistent with these results, raloxifene does not appear 
to cause adverse effect on lipids and lipoproteins. A post-hoc 
analysis reported the effects of raloxifene on lipids and lipo-
proteins in 2659 women with either normal (150 mg/dL) 
or high (150 mg/dL) triglyceride levels from a substudy 
of the MORE trial (Walsh et al 1998). In both triglyceride 
subgroups, raloxifene signiﬁ  cantly improved low-density 
lipoprotein cholesterol, total cholesterol, non-high-density 
lipoprotein cholesterol (HDL-C), apolipoprotein B, 
apolipoprotein A-I, and ﬁ  brinogen compared with placebo 
(p  0.05). After raloxifene treatment, women with high 
triglycerides experienced an equal or greater reduction in 
cholesterol, lipoprotein parameters, and ratios of total cho-
lesterol to HDL-C and non-HDL-C to HDL-C than were 
observed in women with normal triglycerides. Mean levels of 
low-density L-C were reduced by 16.5% and apolipoprotein 
B by15.8% in women with high triglycerides, and by 12.7% 
and 11.3%, respectively, in women with normal triglycer-
ides. These ﬁ  ndings substantiate that raloxifene improves 
concentrations of both cholesterol and beta-lipoprotein. 
The subgroup of women with high triglycerides, who have 
elevated cardiovascular risk, appear to derive at least equal, 
if not greater, overall effect on lipid and lipoprotein lowering 
with raloxifene. These are important safety considerations Clinical Interventions in Aging 2008:3(4) 606
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when evaluating raloxifene for a potential breast cancer risk 
reduction indication.
In the MORE trial, raloxifene increased the risk of 
venous thromboembolic disease (RR, 3.1; 95% CI, 1.5–
6.2), but did not increase the risk of endometrial cancer 
(RR, 0.8; 95% CI, 0.2–2.7). During the CORE trial, the 
relative risk of thromboembolism in the raloxifene group 
(2.9 events per 1000 woman-years) compared with those 
in the placebo group (1.3 events per 1000 woman-years) 
was 2.17 (95% CI = 0.83–5.70) for the CORE enrollees and 
3.11 (95% CI = 0.92–10.44) for the 3200 CORE enrollees 
who resumed taking study medication during the CORE 
trial. During the 8 years of the MORE and CORE trials, 
the incidence rate for venous thromboembolic events was 
2.2 and 1.3 events per 1000 woman-years for the raloxifene 
and placebo groups, respectively. During the CORE trial, no 
cases of pulmonary embolism were reported in the placebo 
group, compared with nine cases reported in the raloxifene 
group (p = 0.066). During the 8 years from randomization in 
MORE until the end of the CORE trial, two women assigned 
to placebo (0.16%) and 17 women assigned to raloxifene 
(0.62%) developed a pulmonary embolism (p = 0.048). 
One death due to pulmonary embolism was reported in the 
raloxifene group during the 4 years of the CORE trial.
RUTH Trial
In the RUTH trial, 4 common adverse events (an acute 
coronary syndrome, anxiety, constipation, and osteopo-
rosis) were reported more frequently in the placebo group 
than in the raloxifene group, and 7 symptoms or adverse 
events (ie, arthritis, cholelithiasis, dyspepsia, hot ﬂ  ushes, 
intermittent claudication, muscle spasm, and peripheral 
edema) were reported more frequently in the raloxifene 
group than in the placebo group. Hot ﬂ  ushes, leg cramps, 
peripheral edema, and gallbladder disease were all statisti-
cally signiﬁ  cantly more common in women assigned to 
raloxifene than to placebo. The rates of cholecystectomy 
did not differ signiﬁ  cantly between the treatment groups 
(p = 0.25). The incidences of endometrial cancer and all 
cancers other than breast cancer did not differ signiﬁ  cantly 
between treatment groups.
Although there was no signiﬁ  cant difference in the rates 
of death from any cause or total stroke according to group 
assignment, raloxifene was associated with an increased risk 
of fatal stroke (59 vs 39 events; HR = 1.49; 95% CI, 1.00–2.24; 
absolute risk increase, 0.7 per 1000 woman-years) and venous 
thromboembolism (HR = 1.44; 95% CI, 1.06–1.95; absolute 
risk increase, 1.2 per 1000 woman-years).
The RUTH trial did not incorporate a global index that 
weighed risks and beneﬁ  ts as was reported in the BCPT 
(Fisher et al 1998), but comparison of the absolute reductions 
and increases in individual end points allows assessment of 
the net risk-beneﬁ  t balance (Barrett-Connor et al 2006). The 
rate of invasive breast cancer was reduced 44% and translates 
to 1.2 fewer cancers per 1000 women treated with raloxifene 
per year among low-risk, older postmenopausal women. The 
rate of clinical vertebral fractures was 3.7 per 1000 women 
per year, and the absolute reduction was 1.3 fractures per 
1000 women-years. These two beneﬁ  ts came at a cost of 1.2 
more cases of venous thromboembolism and 0.7 excess fatal 
strokes per 1000 women-years. For women in the RUTH 
cohort that comprised individuals with or at increased risk 
for coronary heart disease, the moderate beneﬁ  ts of raloxifene 
for breast cancer risk reduction appeared to some observers 
not to justify the risks (Stefanick 2006).
Quality of life, patient satisfaction, 
acceptability, adherence, and uptake
In the STAR trial, patient-reported symptoms were collected 
from all participants using a 36-item symptom checklist 
(Land et al 2006). Quality of life was measured with the 
Medical Outcomes Study Short-Form Health Survey (SF-36) 
(McHorney et al 1992, 1993, 1994; Ware and Sherbourne 
1992), the Center for Epidemiologic Studies-Depression 
(CES-D) (Radloff 1977), and the Medical Outcomes Study 
Sexual Activity Questionnaire (Sherbourne 1992) in a 
substudy of 1983 participants with a median follow-up of 
5.4 years (range, 4.6–6.0 years). Questionnaires were admin-
istered before treatment, every 6 months for 60 months and at 
72 months. Primary quality of life end points were the SF-36 
physical (PCS) and mental (MCS) component summaries.
Among women in the quality of life analysis in STAR, mean 
PCS, MCS, and CES-D scores worsened modestly throughout 
the study with no signiﬁ  cant difference between the tamoxifen 
and raloxifene groups. Sexual function was slightly better 
for participants assigned to tamoxifen. Of the women in the 
symptom assessment analyses, those in the raloxifene group 
reported greater mean symptom severity over 60 months of 
assessments than the women in the tamoxifen group for mus-
culoskeletal problems, dyspareunia, and weight gain. Women in 
the tamoxifen group reported greater mean symptom severity for 
gynecological problems, vasomotor symptoms, leg cramps, and 
bladder control symptoms. No signiﬁ  cant differences existed, 
however, between the tamoxifen and raloxifene groups in 
patient-reported outcomes for physical health, mental health, and 
depression, although the tamoxifen group reported better sexual Clinical Interventions in Aging 2008:3(4) 607
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function. Although mean symptom severity was low among 
these postmenopausal women, those in the tamoxifen group 
reported more gynecological problems, vasomotor symptoms, 
leg cramps, and bladder control problems, whereas women in 
the raloxifene group reported more musculoskeletal problems, 
dyspareunia, and weight gain.
There were 36 cases of uterine cancer with tamoxifen 
and 23 with raloxifene (RR, 0.62; 95% CI, 0.35–1.08). No 
differences were found for other invasive cancer sites, for 
ischemic heart disease events, or for stroke.
Thromboembolic events (ie, pulmonary embolism and 
deep venous thrombosis) occurred less often in the raloxifene 
group (RR, 0.70; 95% CI, 0.54–0.91). The absolute rate of 
venous thromboembolism was signiﬁ  cantly lower among 
women assigned to raloxifene (2.6 per 1000) than among 
those assigned to tamoxifen (3.7 per 1000). The cumula-
tive incidence of serious clotting events at 6 years was 
21.0 per 1000 for the raloxifene group and 16.0 per 1000 for 
raloxifene group. Pulmonary embolism and DVT occurred 
in 54 vs 35 women (RR = 0.64; 95% CI, 0.41–1.00) and in 
87 vs 65 women (RR = 0.74; 95% CI, 0.53–1.03) assigned 
to tamoxifen and raloxifene, respectively.
There were 53 strokes associated with tamoxifen in 
the STAR trial and 51 stroke events among the women 
taking raloxifene. The number of osteoporotic fractures in 
the groups was similar. There were fewer cataracts (RR, 
0.79; 95% CI, 0.68–0.92) and cataract surgeries (RR, 0.82; 
95% CI, 0.68–0.99) in the women taking raloxifene. There 
was no difference in the total number of deaths or in causes 
of death.
Conclusions
The potential market for a compound shown to reduce the risk 
of invasive breast cancer in postmenopausal women who are 
at risk for breast cancer is large (Freedman et al 2003). Of the 
more than 65 million women aged 35–79 without reported 
breast cancer in the US in 2000, more than 10 million women 
(15.5%) would be eligible for tamoxifen chemoprevention 
using the eligibility criteria of the BCPT. In the US, there are 
more than 33 million postmenopausal women, and 9 million 
of these women are eligible for risk reduction with a SERM. 
Of the 50 million white US women aged 35–79, more than 
2 million, or about 5%, would have a positive beneﬁ  t/risk 
index for SERM-based chemoprevention. An estimate of 
the net beneﬁ  t among non-white women is difﬁ  cult due to 
the lack of these women in the clinical trials. Efforts are 
ongoing to increase participation of non-white women in 
risk reduction clinical trials. Among the postmenopausal 
women, 1.2 million women would derive net beneﬁ  t from 
tamoxifen. Among white women in North America, more 
than 28,000 breast cancers would be prevented or deferred 
if those women who have a positive net beneﬁ  t index took 
tamoxifen over the next 5 years. A similar number of women 
in Europe could also derive beneﬁ  t from chemoprevention of 
breast cancer with a SERM. Estimates for the rest of the world 
are not available. Approximately 500,000 women worldwide 
are currently taking raloxifene for the management of 
osteoporosis.
Raloxifene is approved by both the European Union 
and the US Food and Drug Administration (FDA) for the 
prevention and treatment of osteoporosis in postmenopausal 
women. Based on the extensive clinical experience reported 
to date, the FDA approved raloxifene to reduce the risk of 
invasive breast cancer in high-risk, postmenopausal women 
in September 2007. These women would include those with 
high quantitative risks for breast cancer, those with lobular 
carcinoma in situ or atypical ductal or lobular hyperplasia, 
and in women with a history of breast cancer in a ﬁ  rst-degree 
female relative (mother, sister, or daughter).
The ﬁ  ndings from the MORE and CORE trials suggest 
that raloxifene therapy is associated with a reduced risk of 
invasive breast cancer in postmenopausal women irrespec-
tive of the presence or absence of risk factors, but that its 
effect are greater in women with a family history of breast 
cancer. The cumulative results from all of the trials considered 
together indicate that both absolute beneﬁ  ts and absolute risks 
will vary depending on the risk proﬁ  les of women receiving 
treatment. Raloxifene does not signiﬁ  cantly affect the risk of 
cardiac outcome events despite its known favorable effects on 
serum lipids. In addition, in the older population of women in 
RUTH who were at low to average risk of breast cancer, the 
beneﬁ  ts of raloxifene in reducing the risks of invasive breast 
cancer and vertebral fracture were negatively balanced by the 
increased risks of venous thromboembolism and fatal stroke. 
The small difference (0.6 per 1000 woman-years) in the rate 
of non-invasive breast cancer reported in the STAR trial when 
comparing tamoxifen with raloxifene will have a small impact 
on the estimate of the net beneﬁ  t of raloxifene for reducing 
the risk of breast cancer given that non-invasive breast cancer 
is not a life-threatening event and should not diminish the 
perceived utility of raloxifene for this indication.
Raloxifene is a unique SERM with distinct activity and 
toxicity proﬁ  les. Extensive experience from prospective 
investigations has established its safety and efﬁ  cacy in the 
management of postmenopausal osteoporosis. Although it 
has no apparent beneﬁ  cial effect on CHD, it has no adverse Clinical Interventions in Aging 2008:3(4) 608
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effect either. Three prospective clinical trials have established 
its beneﬁ  t in reducing the risk of invasive breast cancer, and 
it offers safety advantages when compared with tamoxifen in 
postmenopausal women who are at increased risk for breast 
cancer. Symptomatic side effects are acceptable as reported 
in the large, prospectively blinded clinical populations 
summarized here and followed during years of raloxifene 
administration. The risk of other cancers, fractures, ischemic 
heart disease, and stroke are similar for both raloxifene and 
tamoxifen. Raloxifene thus offers an alternative to tamoxifen 
for the reduction of breast cancer risk in high-risk postmeno-
pausal women with a superior risk-beneﬁ  t proﬁ  le based upon 
the beneﬁ  ts and risks reviewed here.
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